Reported Side Effects by Dose Level Most gastrointestinal side effects were mild to moderate and occurred primarily during dose escalation
Patients received a 3-week treatment with dulaglutide (1.5 mg) or placebo (0.9% sodium chloride) subcutaneously once weekly and attended an 8-hour evaluation visit during the last treatment week
Cardiovascular warning signssuch as chest pain, shortness of breath, fainting, or a heart rate that drops below 50 beats per minuteshould trigger an emergency call to 911 or your local poison control center
Lack of Directionality in Staging Current staging systems do not indicate whether fibrosis is progressing or regressing within a stage, which makes it difficult to assess the true impact of treatment on disease progression4
Oxidative stress involves various types of neurodegenerative diseases, including Parkinsons, Alzheimers, and Huntingtons diseases
In general, although with exceptions, activated endothelial cells act as the initial stimulus, causing the subsequent recruitment of leukocytes which release a host of pro-fibrotic cytokines like IL-6 and TGF-1, which act on local fibroblasts to create a fibrogenic environment, causing the transition from inactive into aberrantly activated SMA expressing myofibroblasts ( ACTA2 and THY1 (encoding for SMA and CD90, respectively), also contribute to the progression of fibrosis ( JAK2 , and affects the bone marrow ( Chronic wounds are also wounds that fail to heal, but unlike fibrosis, where fibroblasts get 'stuck' in a perpetual proliferative and collagen deposition phase (i.e
